Skip to content
Menu

Citizens Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $22

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.

Citizens analyst Daniel Stauder maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $25 to $22.

Read at benzinga.com

← All stock news